State of the art biological therapies in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a five-year survival rate of approximately 5%. Several target agents have been tested in PDAC, but almost all have failed to demonstrate efficacy in late phase clinical trials, despite the better understanding of PDA...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:World J Gastrointest Oncol
Main Authors: Di Marco, Mariacristina, Grassi, Elisa, Durante, Sandra, Vecchiarelli, Silvia, Palloni, Andrea, Macchini, Marina, Casadei, Riccardo, Ricci, Claudio, Panzacchi, Riccardo, Santini, Donatella, Biasco, Guido
Formato: Artigo
Idioma:Inglês
Publicado em: Baishideng Publishing Group Inc 2016
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4714146/
https://ncbi.nlm.nih.gov/pubmed/26798437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v8.i1.55
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados